Article
Response to trastuzumab deruxtecan in postoperative recurrent lung adenocarcinoma harboring concurrent EGFR and HER2 mutations after progression on adjuvant osimertinib.
Respiratory investigation - 1 Jul 2026
Nishiyama Taketaka, Saruwatari Koichi, Goebuchi Kageaki, Furukawa Tsuguhiro, Naito Daiki, Fukushima Kazuaki, Muramoto Kei, Akaike Kimitaka, Okabayashi Hiroko, Tomita Yusuke, Sakagami Takuro
Abstract excerpt
Epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 (HER2) mutations are key molecular targets in non-small cell lung cancer (NSCLC). We report a rare case of postoperative recurrent lung adenocarcinoma in an 84-year-old woman harboring EGFR L858R and HER2 S310F mutations after progression on adjuvant osimertinib. After further progression on chemotherapy, she received trastuzumab...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.